Autonomix Medical, Inc. (NASDAQ:AMIX) Sees Significant Increase in Short Interest

Autonomix Medical, Inc. (NASDAQ:AMIX) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 58,986 shares, a growth of 119.9% from the September 30th total of 26,830 shares. Based on an average daily volume of 282,590 shares, the short-interest ratio is currently 0.2 days. Currently, 6.4% of the shares of the stock are sold short.

Analyst Ratings Changes

AMIX has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Autonomix Medical in a report on Monday, October 26th. Wall Street Zen raised shares of Autonomix Medical from a “strong sell” rating to a “sell” rating in a report on Saturday, October 3rd. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $42.00.

Autonomix Medical Trading Down 11.3%

Shares of AMIX stock traded down $0.23 on Friday, hitting $1.81. 134,539 shares of the stock were exchanged, compared to its average volume of 180,146. The firm has a market capitalization of $1.76 million, a P/E ratio of -0.04 and a beta of -0.96. The business has a 50-day moving average of $3.82 and a 200 day moving average of $6.82. Autonomix Medical has a fifty-two week low of $1.81 and a fifty-two week high of $32.55.

Autonomix Medical (NASDAQ:AMIX) last announced its earnings results on Wednesday, August 12th. The company reported ($5.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($6.40) by $1.38. As a group, research analysts forecast that Autonomix Medical will post -20.17 EPS for the current fiscal year.

About Autonomix Medical

Autonomix Medical, Inc is a medical device company developing catheter-based technologies for the detection and treatment of conditions involving the peripheral nervous system. The company’s platform is designed to identify neural signals in real time, with the goal of helping physicians locate and selectively treat targeted nerves during minimally invasive procedures.

Autonomix’s lead development program is focused on pain associated with pancreatic cancer. Its technology is intended to support targeted nerve ablation, potentially offering an alternative approach for managing pain while reducing the need for more extensive procedures.